MentalHealthDaily

Ubiquinol for Multiple System Atrophy: First Positive Repurposing Trial

by GLOOM

Photoreal illustration of misfolded alpha-synuclein in glial cells with drug molecule motifs, representing repurposed-drug therapeutics in MSA.

Multiple system atrophy is a rapidly progressive neurodegenerative disease with no proven disease-modifying therapy. A 2026 review by Jeong and colleagues tracks two decades of repurposed-drug trials, with one recent positive Phase 2 result.1 Research Highlights Multiple system atrophy (MSA) is a fatal α-synuclein disorder distinct from Parkinson’s disease. It progresses faster than PD (median …

Calorie Restriction (CR) Effects on Brain Gene Expression & Behavior in Rats (2023 Study)

by GLOOM

Calorie restriction (CR) is increasingly recognized for its potential benefits beyond just weight loss, including reducing anxiety, slowing aging, and mitigating the risk of obesity. Recent research focused on how both short-term and long-term CR affect behavior and gene expression in various brain regions, providing insights into the molecular underpinnings of these effects. Highlights: Behavioral …